Social Capital Suvretta Holdings Corp. II: directors' dealings · United States · SEC (Form 4)

About Social Capital Suvretta Holdings Corp. II

Social Capital Suvretta Holdings Corp. II is a U.S.-listed SPAC (special purpose acquisition company) that traded on the NASDAQ market in the United States. At inception, it was not an operating business with commercial products or recurring revenue; instead, it was formed to raise capital and pursue a merger, share exchange, asset acquisition, or similar business combination with one or more private companies. In its IPO materials, the company said it was led by Chamath Palihapitiya and Kishen Mehta and that its investment focus would be biotechnology, with a particular emphasis on oncology. The company priced its upsized IPO in June 2021, selling 22 million Class A ordinary shares at $10.00 per share and listing on the Nasdaq Capital Market under the symbol DNAB. ([nasdaq.com](https://www.nasdaq.com/press-release/social-capital-suvretta-holdings-corp.-ii-announces-pricing-of-upsized-%24220000000?utm_source=openai)) From an equity research perspective, Social Capital Suvretta Holdings Corp. II should be viewed as an event-driven vehicle rather than a conventional healthcare company. Its economics were tied to the sponsor’s ability to identify a compelling target, negotiate terms, secure shareholder support, and complete a business combination. That means the investment case depends less on operating KPIs and more on transaction quality, valuation discipline, redemption levels, and the post-merger equity story. The company’s stated sector preference for biotechnology and oncology was important because it narrowed the deal search toward a large and scientifically attractive segment of the U.S. healthcare market. ([nasdaq.com](https://www.nasdaq.com/press-release/social-capital-suvretta-holdings-corp.-ii-announces-pricing-of-upsized-%24220000000?utm_source=openai)) The competitive advantage of a SPAC like this is not product breadth, but access to private-market opportunities, sponsor credibility, and the ability to provide an alternative public-listing route for a target. Suvretta Capital Management’s involvement added healthcare and life-sciences credibility, while the broader Social Capital brand offered visibility in the U.S. growth-investing ecosystem. The company was headquartered in Palo Alto, California, which placed it close to both venture financing networks and the biotechnology innovation cluster on the U.S. West Coast. For international investors, that location matters because it signals proximity to deal flow in one of the deepest healthcare innovation markets in the world. ([nasdaq.com](https://www.nasdaq.com/press-release/social-capital-suvretta-holdings-corp.-ii-announces-pricing-of-upsized-%24220000000?utm_source=openai)) Key recent developments around the company were primarily corporate rather than operational: IPO execution, SEC filings, and subsequent transaction-related disclosures. Since the company’s value proposition was built around completing a business combination, any Form 4 insider activity or SEC amendment should be read in the context of governance, sponsor alignment, and deal progress rather than earnings momentum. In short, Social Capital Suvretta Holdings Corp. II is best analyzed as a U.S. NASDAQ-listed, biotech-oriented SPAC whose market relevance comes from its transaction pipeline, not from standalone products or manufacturing operations. ([nasdaq.com](https://www.nasdaq.com/press-release/social-capital-suvretta-holdings-corp.-ii-announces-pricing-of-upsized-%24220000000?utm_source=openai))